Q4 2025 Management View CEO Lachlan Given described fiscal 2025 as "a transformative year for EZCORP," marked by record revenue of $1.3 billion, a 12% year-over-year increase, and adjusted EBITDA of ...

Assembly Biosciences is experiencing a dramatic stock rally following the release of groundbreaking clinical trial results.

Arch Capital has notably trailed the broader market over the past year, but analysts remain fairly confident in the company’s ...

Q3 2025 Earnings Call November 14, 2025 10:00 AM ESTCompany ParticipantsZach VaughanDwayne Hyzak - CEO & Chairman of ...

The investment community is buzzing with renewed optimism for Robinhood Markets following the fintech platform's impressive third-quarter earnings release. M ...

Bay's stock price target has seen a modest uptick, with consensus analyst estimates moving from $91.55 to $94.93. This subtle shift reflects a mix of analyst optimism and healthy skepticism, fueled by ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...

Precigen, Inc. ( PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good afternoon, ladies and gentlemen, and welcome to the Precigen Third Quarter 2025 Financial Results and Business Update ...

CoreWeave (NASDAQ:CRWV) reported Q3 results, and the numbers were impressive – revenue more than doubled from last year, and losses narrowed as ...

In the assessment of 12-month price targets, analysts unveil insights for CoreWeave, presenting an average target of $151.73, ...

Results from the PATHFINDER 2 trial of Grail's blood test for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology. The Galleri ...